Bedside Snapshot
- Use It For
- Symptomatic hypoglycemia (glucose under 70 mg/dL) in an alert patient who can swallow safely; most often in insulin- or sulfonylurea-treated diabetes
- Adult Dose
- Alert, swallowing safely per ADA 2026: 15 g PO; recheck glucose at 15 min and repeat 15 g if still under 70 mg/dL
- Alternative protocol per NASEMSO 2022: 25 g PO
- Pediatric Dose
- 0.3 g/kg PO per ISPAD 2022 (about 15 g over 50 kg). NASEMSO 2022: 0.5–1 g/kg PO, no oral cap; do not exceed the adult dose without medical direction. Not by mouth if the child cannot swallow safely
- Onset / Duration
- PO: partial rise by 10–15 min in pediatric data (about 18–38 mg/dL); full rise about 45 min (45–65 mg/dL with 20 g adult tablets). Duration depends on insulin or sulfonylurea action; feed the patient after recovery
- Do Not Give / Hold If
- Not alert, unable to swallow safely, vomiting or drooling; no documented or strongly suspected hypoglycemia
- Watch For
- Aspiration in drowsy patients (side-lying, suction ready); recurrence after sulfonylurea or long-acting insulin; overshoot hyperglycemia with repeated doses or automated insulin delivery
- Reversal / Rescue
- Not alert or not swallowing: IV/IO dextrose in incremental doses (see Dextrose) or glucagon 1 mg IM/subcut/IV or 3 mg IN (see Glucagon); glucagon: one more dose at 15 min if no response, per the Glucagon page
- Must Remember
- Oral glucose is for the alert patient only: check glucose before the dose and 15 min after, repeat if still low, then feed the patient
Indications
Emergency & Prehospital
- Symptomatic hypoglycemia in an alert patient who can swallow safely: this is the first move when glucose is under 70 mg/dL (ADA 2026 alert value). NASEMSO 2022 inclusion criteria cover glucose under 60 mg/dL with symptoms. Its treatment step gives oral glucose at 60 mg/dL or less. Follow the local threshold
- Hypoglycemia in a patient on insulin or a sulfonylurea: the usual setting. Check glucose first. With long-acting drugs, expect it to come back (see insulin)
- Hypoglycemia first aid at home, school or work: ADA 2026 puts oral glucose in first aid kits. Only an alert person should use it
ED / ICU / Transport
- ADA 2026 levels: level 1 is under 70 mg/dL and 54 mg/dL or above. Level 2 is under 54 mg/dL and needs immediate action. Level 3 is a severe event where the patient needs help from another person, whatever the glucose. Level 3 events are not oral-glucose cases. Use non-oral treatment per protocol
- Level 1 hypoglycemia (under 70 mg/dL) in a patient who can eat: fast-acting carbohydrate, then recheck at 15 min per ADA 2026
- Completing treatment after IV dextrose or glucagon: once the patient is awake and can swallow, feed them a meal or snack. That keeps glucose from falling again
Dosing & Administration
Doses vary by protocol; follow local protocols and medical direction.
Available Forms
- Glucose gel: a gel in a tube for the alert patient. Count the grams on the package. The tube's weight tells you nothing about glucose. If one unit holds 15 g, a 25 g dose takes more than one unit
- Glucose tablets: chewable. Count the grams on the label. When it is available, ISPAD 2022 puts glucose-based products first
- Juice, candy, table sugar or cake icing: no dose is established for these. ISPAD 2022 notes that about 40 g of juice raises glucose about as much as 20 g of glucose tablets
- Not an IV product: IV dextrose lives on the Dextrose page. Glucagon lives on the Glucagon page
Adult Dosing
| Indication | Dose & Route | Repeat / Max | Notes |
|---|---|---|---|
| Hypoglycemia, alert and swallowing safely per ADA 2026 | 15 g PO, given in full as the initial dose | Recheck glucose at 15 min; repeat 15 g if still under 70 mg/dL and still alert. No fixed cumulative max: titrate to glucose and alertness | Grams from the package label. Pure glucose is preferred. Automated insulin delivery users: 5–10 g per ADA 2026. Feed once recovered. |
| Hypoglycemia, alternative protocol per NASEMSO 2022 | 25 g PO | Single dose 25 g; recheck glucose and mental status before any repeat. No cumulative max stated in the source | Protocol-dependent and larger than the ADA 2026 dose. Choose one dose per agency protocol. |
| Unalert or cannot swallow safely | No oral dose: IV/IO dextrose 10 g (100 mL D10), or glucagon 1 mg IM/subcut/IV or 3 mg IN | IV/IO dextrose in incremental doses until mental status improves, to a maximum field dose of 25 g (NASEMSO 2022; step size per the Dextrose page); glucagon: one more dose at 15 min if no response, per the Glucagon page |
Pediatric Dosing
| Indication | Dose (per kg) & Route | Max Single / Max Total | Notes |
|---|---|---|---|
| Hypoglycemia, alert and swallowing safely per ISPAD 2022 | 0.3 g/kg PO (about 15 g at over 50 kg) | No explicit ISPAD maximum; its examples are 9 g at 30 kg and 15 g at over 50 kg. No fixed cumulative max: recheck at 15 min and repeat | Aim to raise glucose by 3–4 mmol/L (54–72 mg/dL). In a pediatric study, the dose raised median glucose by 1–1.3 mmol/L (18–23 mg/dL) at 10 min and 2–2.1 mmol/L (36–38 mg/dL) at 15 min: a partial rise, not full correction. |
| Hypoglycemia, protocol alternative per NASEMSO 2022 | 0.5–1 g/kg PO | NASEMSO states no oral cap. Page inference: for a larger child, do not exceed the adult dose (25 g NASEMSO; 15 g ADA) without medical direction. Recheck glucose at 15 min before repeating | Higher than the ISPAD 2022 dose. A literal 1 g/kg in a 50 kg child is 50 g, double the adult NASEMSO dose. Weigh the child; do not dose by age. Confirm the cap with medical direction. |
| Unalert, or cannot swallow safely | Not by mouth: IV/IO dextrose 5–10 mL/kg of D10 (2 mL/kg for newborns), or glucagon | Per the Dextrose and Glucagon pages. NASEMSO 2022 glucagon: 0.5 mg IM/IN if under 20 kg | Never give oral glucose to a child who cannot swallow safely. Newborns follow the neonatal protocol. |
Preparation & Administration
- Preparation: Nothing to mix. Use it as packaged, and read the grams on the label before you give it.
- Who and when: alert, able to swallow, and able to follow commands. Check glucose before the dose and 15 min after per ADA 2026.
- Position: Upright or side-lying. Have suction ready if the patient drools or vomits.
- Insulin pump: for hypoglycemia with altered mental status (GCS under 15), NASEMSO 2022 says to act on the pump. If the patient cannot ingest oral glucose or ALS is not available, stop it, disconnect it or remove it at the insertion site. If the patient can take oral glucose or receive ALS interventions, leave it connected and running.
Dosing Notes:
- Dietary sugars: no established dose. ISPAD 2022 says you need more grams than with glucose
- Protein may raise insulin release, so don't use it for hypoglycemia. Fat slows the rise, per ADA 2026
- Acarbose: pure glucose only. Acarbose slows the breakdown of sucrose, per ADA 2026
- Automated insulin delivery: 5–10 g, unless the low is exercise-related or the meal bolus was overestimated, per ADA 2026
Contraindications & Precautions
Contraindications
- Not alert, or unable to swallow safely: aspiration is the risk. ADA 2026 limits oral glucose to an alert person. NASEMSO 2022 limits it to conscious patients with a patent airway
- Normal glucose: don't treat a normal reading with sugar. Look for another cause of altered mentation
- Glucose gel and tablets have no labeled drug contraindications. They are not FDA-labeled drug products. The limits above come from ADA 2026 and NASEMSO 2022.
Precautions
- Aspiration: drowsiness, vomiting or a weak gag reflex. Use side-lying and suction. Stop if the patient coughs or gurgles
- Acarbose: pure glucose only. Sucrose (table sugar) delays the correction, per ADA 2026
- Sulfonylureas and long-acting insulin: the drug outlasts the sugar. NASEMSO 2022 gives sulfonylurea half-lives of 12–60 hr. Expect recurrence and plan observation
- Automated insulin delivery: use smaller doses, 5–10 g, to reduce rebound hyperglycemia, per ADA 2026 and ISPAD 2022
- Limited evidence in type 2 diabetes: a 2026 systematic review found only three studies. The 15 g and 15-minute rule rests mainly on expert opinion (see References)
Hold / Reassess If
- Patient alert and glucose at or above 70 mg/dL: stop treating and feed the patient (ADA alert value)
- Patient not alert, or coughing, gurgling or vomiting: stop oral intake and move to IV/IO dextrose or glucagon
- Glucose still under 70 mg/dL at 15 min and patient still alert: repeat 15 g per ADA 2026
- No response after a repeat dose: escalate to IV/IO dextrose per the Dextrose page and transport
Airway first: If the patient cannot protect the airway, glucose gel or tablets can go into the lungs. Give nothing by mouth. Treat with IV/IO dextrose or glucagon.
Adverse Effects & Toxicity
Common
- Rebound hypoglycemia: the low returns when insulin or a sulfonylurea is still active after the sugar is used up
- Overshoot hyperglycemia: it is more likely with larger or repeated doses and with automated insulin delivery, per ISPAD 2022
- Incomplete correction at the first recheck: the first recheck does not always show full correction. The 2026 type 1 diabetes review found that only some studies reached more than 50% resolution at that recheck (see References)
Serious / Life-Threatening
| Effect | Recognition | Management |
|---|---|---|
| Aspiration | Coughing, gurgling or drooling after a dose; falling SpO₂ | Stop oral intake; suction; side-lying position; airway support; treat as unalert |
| Recurrent hypoglycemia | Confusion or low glucose after recovery, with sulfonylurea, long-acting insulin or insulin overdose | Recheck glucose; IV dextrose infusion per the Dextrose page; transport per protocol; for sulfonylurea toxicity, octreotide per poison center advice |
| Severe overshoot hyperglycemia | Glucose well above target after treatment, more likely with repeated doses or automated insulin delivery | Recheck glucose; stop further sugar; manage per protocol and see the insulin page |
Overdose & Toxicity Management
- Signs: the sources reviewed define no toxic dose. Big or repeated doses push glucose too high
- Management: check glucose, stop oral sugar and treat hyperglycemia per protocol
- Antidote: there is no antidote. The danger is the low itself. Rescue doses are on the Dextrose page
Monitoring
| Parameter | When / How Often | Target / Act If |
|---|---|---|
| Clinical: alertness and swallowing | Before each oral dose | Not alert, or coughing or drooling with sips: no oral glucose; IV/IO dextrose or glucagon |
| Clinical: point-of-care glucose | Before the dose, 15 min after, and until stable per ADA 2026 | Under 70 mg/dL and alert: repeat 15 g. At or above 70 mg/dL: stop and feed (see glucose) |
| Clinical: mental status and vital signs | After each dose and during transport | No improvement: escalate to IV/IO dextrose. Persistent confusion at a normal glucose: look for another cause |
| Observation: recurrence | Sulfonylurea or long-acting insulin, for hours after the sugar | Recurrent low glucose: IV dextrose and transport per protocol (see the Dextrose page) |
| Release decision | Before any release without transport per NASEMSO 2022 | Release only if repeat glucose is over 80 mg/dL and the other protocol criteria are met; otherwise transport |
Interactions & Compatibility
Clinically Significant Interactions
| Drug / Class | Effect | What To Do |
|---|---|---|
| Insulin (rapid or long-acting) | Glucose rises briefly while insulin keeps lowering it | Repeat glucose; feed after recovery; observe |
| Sulfonylureas (glipizide, glyburide) | Insulin release continues for many hours (half-life 12–60 hr, per NASEMSO 2022) | Expect recurrence; plan observation; octreotide per poison center advice (see the Dextrose page) |
| Acarbose (alpha-glucosidase inhibitor) | Blocks sucrose breakdown, so sucrose delays correction | Use pure glucose only per ADA 2026 |
| Protein or fat foods | Protein may raise insulin release; fat slows the glucose rise | Use a glucose-based product first, not a meal per ADA 2026 |
| Alcohol or starvation | Liver glycogen is low, so glucagon may fail. Oral glucose does not need liver glycogen | Oral glucose still works; give thiamine with or before dextrose (see the Dextrose page) |
This is not an IV product, so IV compatibility is not a question here. For IV dextrose compatibility, go to the Dextrose page.
Special Populations
- Pediatrics: weight sets the dose: 0.3 g/kg per ISPAD 2022, or 0.5–1 g/kg per NASEMSO 2022. A child who cannot swallow safely gets no oral glucose. Infants and toddlers may not follow commands or swallow reliably. Give oral glucose only to a child who is awake, has a patent airway and can swallow (NASEMSO 2022 conscious-patient criterion). Hard chewable tablets are a choking risk in young children. That is a page caution, not stated in ISPAD or NASEMSO. Use a gel or liquid form only when the child is awake and swallowing reliably. See the Pediatric Dosing table.
- Neonates: a newborn who cannot swallow reliably does not get oral glucose in the field. Neonatal hypoglycemia follows the neonatal protocol. Go to the Dextrose page for neonatal IV dosing.
- Pregnancy: the sources reviewed found no pregnancy-specific adjustment. The same alert-patient rule applies. Treat hypoglycemia promptly.
- Lactation: no specific adjustment established.
- Older Adults: a low can look like a stroke, a fall or dementia. Check glucose early. Drowsiness and swallowing problems raise the aspiration risk.
- Renal Impairment: no dose adjustment for oral glucose. Kidney failure keeps insulin working longer. Expect recurrence (see the Dextrose page).
- Hepatic Impairment: no dose adjustment is established. Absorbed glucose does not need liver glycogen, unlike glucagon. Still, recheck glucose as you would for any patient.
- Obesity / Dosing Weight: the adult dose stays fixed. The pediatric dose runs on actual body weight in kg.
- Automated Insulin Delivery: use 5–10 g, unless the low is exercise-related or the meal bolus was overestimated, per ADA 2026. ISPAD 2022 notes rebound hyperglycemia with standard doses.
Field & Transport Considerations
- Scope: a treatment for conscious patients in the NASEMSO 2022 hypoglycemia guideline. Commonly EMT-level, but it varies by state and agency protocol.
- Storage & Stability: keep at room temperature and out of hot vehicle compartments; check the expiration date. Follow the product label.
- Carried Concentration: this is not a concentrated solution. Dose by the grams on the label. The IV alternative is D10 (100 mg/mL), per the Dextrose page.
- Insulin Pumps: for hypoglycemia with altered mental status (GCS under 15), NASEMSO 2022 has a rule for the pump. If the patient cannot ingest oral glucose, or ALS is not available, stop it, disconnect it or remove it at the insertion site. If the patient can take oral glucose or receive ALS interventions, leave it running.
- Release Criteria: NASEMSO 2022 allows release without transport only when all of these hold. Repeat glucose is over 80 mg/dL. Mental status is normal. The patient eats a meal. A reliable adult stays. There are no co-morbid symptoms. The cause is clear. Patients on long-acting sulfonylureas are not released. Seizure patients go to hospital regardless.
- Handoff Essentials: time, initial glucose, grams given, product, glucose at 15 min, mental status, whether the patient ate, and whether a sulfonylurea or long-acting insulin is involved.
Clinical Pearls
Alert only: A drowsy patient can aspirate sugar, and the airway comes first. ADA 2026 limits oral glucose to an alert person. Anyone who is not alert gets IV/IO dextrose or glucagon.
15 g is a starting point: The 15 g and 15-minute rule rests on two small studies of IV-insulin hypoglycemia in type 1 diabetes. The standard still builds in a repeat dose. Recheck, then repeat.
Exam discriminator: oral glucose vs glucagon: Oral glucose does not need liver glycogen, so it still works in starvation or alcohol use. Glucagon releases stored glycogen, and it fails when that store is empty. Oral glucose needs a patient who can swallow. Glucagon does not.
Sulfonylureas bring the low back: The sugar stops the low. The drug keeps pushing insulin out for hours. Feed, recheck and observe. Don't call the first correction the end of the event.
Acarbose users need pure glucose: Table sugar is sucrose. Acarbose slows its breakdown, so the correction runs late, per ADA 2026.
Oral, IV or glucagon:
- Oral glucose: alert patient who swallows safely; 15 g per ADA 2026
- IV/IO dextrose: unalert patient, no oral route; 10 g D10 IV (see the Dextrose page)
- Glucagon: no IV access or cannot swallow; 1 mg IM/subcut/IV or 3 mg IN (see the Glucagon page)
Glucose beats dietary sugar: ISPAD 2022 reports that glucose tablets relieve symptoms more reliably at 15 min than candy, table sugar or juice. Juice needs about twice the grams.
Pharmacology
Mechanism of Action
- The small intestine absorbs glucose into the blood. The brain and other tissues then use it directly. No receptor is involved.
- Higher plasma glucose reverses neuroglycopenia and the adrenergic symptoms of hypoglycemia.
- Clinical consequence: the effect ends once the glucose is used up. If insulin or a sulfonylurea is still active, the low comes back.
Pharmacokinetics
| Route | Onset | Peak | Duration |
|---|---|---|---|
| PO (tablets or gel) | Partial rise by 10–15 min (pediatric study, 0.3 g/kg: 18–23 mg/dL at 10 min, 36–38 mg/dL at 15 min) | Not defined; full rise measured at 45 min with 20 g adult tablets (45–65 mg/dL) | Until the cause is treated; ends as glucose is used. Feed the patient |
- Half-life: not applicable. Glucose is a nutrient, not a drug with a defined half-life.
- Metabolism: glycolysis in tissues, mainly the brain and muscle. Any excess is stored as glycogen.
- Elimination: glucose spills into urine only when plasma levels exceed the renal threshold.
Names & Classification
- Generic Name
- Glucose (dextrose, D-glucose), oral
- Brand Names
- Commercial glucose gels and tablets (product-specific; not FDA-labeled drug products; no product label was reviewed for this page)
- Pharmacologic Class
- Monosaccharide carbohydrate
- Therapeutic Class
- Hypoglycemia treatment (dietary carbohydrate)
- Controlled Substance
- Not controlled
- ISMP High-Alert
- No (IV dextrose 20% or stronger is high-alert: see the Dextrose page)
- Look-Alike / Sound-Alike
- None commonly reported
References
- American Diabetes Association Professional Practice Committee. (2026). 6. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of Care in Diabetes—2026. Diabetes Care, 49(Suppl 1), S132–S149. https://doi.org/10.2337/dc26-S006
- Abraham, M. B., Karges, B., Dovc, K., Naranjo, D., Arbelaez, A. M., Mbogo, J., et al. (2022). ISPAD Clinical Practice Consensus Guidelines 2022: Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatric Diabetes, 23(8), 1322–1340. https://doi.org/10.1111/pedi.13443
- National Association of State EMS Officials, Medical Directors Council. (2022). National Model EMS Clinical Guidelines, Version 3.0: Hypoglycemia (General Medical, revised March 2022, pp. 84–87). https://hhs.iowa.gov/media/198/download
- Prince, N. L., Lochnan, H. A., Shorr, R., Garon-Mailer, A., & Sun, C. J. (2026). Systematic review of oral carbohydrate treatment for non-severe hypoglycemia in type 1 diabetes: a comparison of insulin management systems. Diabetes, Metabolic Syndrome and Obesity. https://doi.org/10.2147/DMSO.S568538
- Prince, N. L., Lochnan, H. A., Shorr, R., Garon-Mailer, A., & Sun, C. J. (2026). Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-025-02144-3
- Hospira, Inc. (2026). Dextrose Injection (50%) [prescribing information] (revised January 2026). DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ed365da-4e62-4329-c1b9-c197ab4fb6e1
Medical Disclaimer
- For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
- Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
- Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing, paraphrasing, and formatting this information.